Amyloidosis - Pipeline Review, H2 2018

  • ID: 4592435
  • Report
  • 196 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Akcea Therapeutics Inc
  • Arcturus Therapeutics Ltd
  • Celgene Corp
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc
  • MORE
Amyloidosis - Pipeline Review, H2 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Amyloidosis - Pipeline Review, H2 2018, provides an overview of the Amyloidosis (Metabolic Disorders) pipeline landscape.

Abnormal accumulation of amyloid protein in the tissues results in a group of diseases known as amyloidosis. It may affect the shape and functioning of the organ eventually leading to organ failure. Predisposing factors are misfolding of abnormal protein called the light chain and its subsequent deposition in the body. It may also occur as a result of dialysis. Symptoms include fatigue, chest pain, swelling and breathing problems. Amyloidosis can be managed by transplant and, medication such as diuretics and chemotherapy drugs.

Report Highlights:

This latest pipeline guide Amyloidosis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Amyloidosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Amyloidosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Amyloidosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 2, 2, 10, 6, 8 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 1 and 2 molecules, respectively.

Amyloidosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Amyloidosis (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Amyloidosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Amyloidosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Amyloidosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Amyloidosis (Metabolic Disorders)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Amyloidosis (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Amyloidosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Akcea Therapeutics Inc
  • Arcturus Therapeutics Ltd
  • Celgene Corp
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc
  • MORE
Introduction

Report Coverage

Amyloidosis - Overview

Amyloidosis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Amyloidosis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Amyloidosis - Companies Involved in Therapeutics Development

Akcea Therapeutics Inc

Alnylam Pharmaceuticals Inc

Amgen Inc

Arcturus Therapeutics Ltd

Bsim

Celgene Corp

Chugai Pharmaceutical Co Ltd

GlaxoSmithKline Plc

Johnson & Johnson

Millennium Pharmaceuticals Inc

Neurimmune Holding AG

Novartis AG

Oncopeptides AB

Pfizer Inc

Prothena Corp Plc

R Pharm

Regeneron Pharmaceuticals Inc

Spectrum Pharmaceuticals Inc

Amyloidosis - Drug Profiles

AG-10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AKCEA-TTR-LRx - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALN-TTRsc02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CAEL-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

canakinumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

carfilzomib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target CS1 for Metabolic Disorders and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLR-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

daratumumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dezamizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dezamizumab + miridesap - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

doxycycline hyclate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EDE-1307 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eprodisate disodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-3039294 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

inotersen sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ixazomib citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LUNAR-TTR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melphalan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melphalan flufenamide hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

miridesap - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit LECT2 for Amyloidosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Target CD66b for Blood Cancer and Metabolic Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NI-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPT-189 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotides to Inhibit Transthyretin for Amyloidosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

patisiran - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pomalidomide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRX-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RPH-104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Amyloid Beta Peptide for Alzheimer's Disease and Amyloidosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate ATF6 for Amyloidosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Cardiomyopathy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Polyneuropathy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tafamidis meglumine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tocilizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tolcapone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VERU-111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VERU-112 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Amyloidosis - Dormant Projects

Amyloidosis - Discontinued Products

Amyloidosis - Product Development Milestones

Featured News & Press Releases

Jul 05, 2018: New England Journal of Medicine Publishes Results from Pivotal Study of TEGSEDI for the Treatment of Hereditary ATTR Amyloidosis

Jul 04, 2018: Alnylam Announces Publication of APOLLO Phase 3 Clinical Study Results for Investigational RNAi Therapeutic Patisiran in The New England Journal of Medicine

Jun 25, 2018: Caelum Biosciences Announces Complete Cardiac Data Analysis from Phase 1b Trial of CAEL-101 in AL Amyloidosis

Jun 18, 2018: Caelum Biosciences Announces Presentation of Complete Cardiac Data Analysis from Phase 1b Trial of CAEL-101 in AL Amyloidosis at American Society of Echocardiography 29th Annual Scientific Sessions

Jun 15, 2018: Alnylam to Report New Clinical Results for Patisiran at the 4th Congress of the European Academy of Neurology

Jun 04, 2018: Alnylam Receives Orphan Drug Designation from the United States Food & Drug Administration for ALN-TTRsc02, a Subcutaneously Delivered Investigational RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis

May 23, 2018: FDA Grants Breakthrough Therapy Designation for Tafamidis for the Treatment of Patients with Transthyretin Cardiomyopathy

May 08, 2018: Alnylam Reports Preclinical Data Demonstrating Central Nervous System Delivery of RNAi Therapeutics

May 03, 2018: Eidos Therapeutics Initiates Phase 2 Clinical Trial for AG10 Targeting Transthyretin Amyloidosis Cardiomyopathy

May 03, 2018: Eidos Therapeutics Initiates Phase 2 Clinical Trial for AG10 Targeting Transthyretin Amyloidosis Cardiomyopathy

Apr 25, 2018: Genmab to Present Data on Daratumumab at 2018 ASCO Annual Meeting

Apr 24, 2018: Alnylam Reports New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the American Academy of Neurology 2018 Annual Meeting

Apr 23, 2018: Alnylam Receives Positive Opinion for Orphan Drug Designation in the European Union for ALN-TTRsc02, a Subcutaneously Delivered Investigational RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis

Apr 21, 2018: Akcea Therapeutics to Present Data on Inotersen for the Treatment of hATTR Amyloidosis at the 2018 American Academy of Neurology Annual Meeting

Apr 03, 2018: Silence Therapeutics: Litigation Update (Portugal and US)

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Amyloidosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Amyloidosis - Pipeline by Akcea Therapeutics Inc, H2 2018

Amyloidosis - Pipeline by Alnylam Pharmaceuticals Inc, H2 2018

Amyloidosis - Pipeline by Amgen Inc, H2 2018

Amyloidosis - Pipeline by Arcturus Therapeutics Ltd, H2 2018

Amyloidosis - Pipeline by Bsim2, H2 2018

Amyloidosis - Pipeline by Celgene Corp, H2 2018

Amyloidosis - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2018

Amyloidosis - Pipeline by GlaxoSmithKline Plc, H2 2018

Amyloidosis - Pipeline by Johnson & Johnson, H2 2018

Amyloidosis - Pipeline by Millennium Pharmaceuticals Inc, H2 2018

Amyloidosis - Pipeline by Neurimmune Holding AG, H2 2018

Amyloidosis - Pipeline by Novartis AG, H2 2018

Amyloidosis - Pipeline by Oncopeptides AB, H2 2018

Amyloidosis - Pipeline by Pfizer Inc, H2 2018

Amyloidosis - Pipeline by Prothena Corp Plc, H2 2018

Amyloidosis - Pipeline by R Pharm, H2 2018

Amyloidosis - Pipeline by Regeneron Pharmaceuticals Inc, H2 2018

Amyloidosis - Pipeline by Spectrum Pharmaceuticals Inc, H2 2018

Amyloidosis - Dormant Projects, H2 2018

Amyloidosis - Discontinued Products, H2 2018

List of Figures

Number of Products under Development for Amyloidosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Akcea Therapeutics Inc
  • Alnylam Pharmaceuticals Inc
  • Amgen Inc
  • Arcturus Therapeutics Ltd
  • Bsim2
  • Celgene Corp
  • Chugai Pharmaceutical Co Ltd
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Millennium Pharmaceuticals Inc
  • Neurimmune Holding AG
  • Novartis AG
  • Oncopeptides AB
  • Pfizer Inc
  • Prothena Corp Plc
  • R Pharm
  • Regeneron Pharmaceuticals Inc
  • Spectrum Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll